Financial reports
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
21 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
Current reports
8-K
Other Events
27 Mar 24
8-K
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
22 Mar 24
8-K
Professor René Bernards to Present New Pre-Clinical Data
27 Feb 24
8-K
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
26 Feb 24
8-K
Other Events
30 Jan 24
8-K
Departure of Directors or Certain Officers
28 Nov 23
8-K
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
13 Nov 23
8-K
Entry into a Material Definitive Agreement
17 Oct 23
8-K
Termination of a Material Definitive Agreement
4 Oct 23
8-K
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
27 Sep 23
Registration and prospectus
S-3
Shelf registration
23 Apr 24
S-3
Shelf registration
11 Aug 23
D
$3.50 mm in options, sold $3.50 mm, 1 investor
1 Aug 23
424B5
Prospectus supplement for primary offering
20 Jul 23
424B5
Prospectus supplement for primary offering
9 May 23
S-8
Registration of securities for employees
16 Dec 22
424B5
Prospectus supplement for primary offering
14 Apr 22
424B5
Prospectus supplement for primary offering
20 Sep 21
S-8
Registration of securities for employees
21 Apr 21
424B5
Prospectus supplement for primary offering
1 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
10 Oct 23
DEF 14A
Definitive proxy
10 Oct 23
PRE 14A
Preliminary proxy
29 Sep 23
DEF 14A
Definitive proxy
11 Apr 23
PRE 14A
Preliminary proxy
24 Mar 23
DEFA14A
Additional proxy soliciting materials
26 Aug 22
DEF 14A
Definitive proxy
26 Aug 22
PRE 14A
Preliminary proxy
15 Aug 22
DEF 14A
Definitive proxy
25 May 21
DEFA14A
Additional proxy soliciting materials
25 May 21
Other
EFFECT
Notice of effectiveness
22 Aug 23
CORRESP
Correspondence with SEC
18 Aug 23
UPLOAD
Letter from SEC
15 Aug 23
EFFECT
Notice of effectiveness
8 Feb 21
CORRESP
Correspondence with SEC
3 Feb 21
UPLOAD
Letter from SEC
2 Feb 21
EFFECT
Notice of effectiveness
25 Nov 20
CORRESP
Correspondence with SEC
19 Nov 20
CORRESP
Correspondence with SEC
19 Nov 20
CERT
Certification of approval for exchange listing
18 Nov 20
Ownership
4
der Baan Bastiaan Jeroen van
16 Oct 23
4/A
Rene Bernards
5 Oct 23
4
der Baan Bastiaan Jeroen van
5 Oct 23
4
Rene Bernards
4 Oct 23
4
der Baan Bastiaan Jeroen van
27 Sep 23
4
der Baan Bastiaan Jeroen van
7 Jul 23
4
Yun Yen
7 Jul 23
4
Regina Brown
7 Jul 23
4
Stephen J. Forman
7 Jul 23
4/A
der Baan Bastiaan Jeroen van
5 Jan 23